Clinicopathological and hypermethylation detection data of 50 kidney cancer patients
Age (years); grade, American Joint Committee on Cancer; pTNM:p, pathologic stage; T, tumor size; N, node status; M, metastatic status; stage, American Joint Committee on Cancer stage grouping, oncocytomas are not graded or staged, and all were confined to the kidney.
| No. | Age/Sex | Cell Type | Size (cm) | Grade | TNM | Stage | VHL | RASSF1A | p16 | p14 | APC | Timp-3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 43M | Clear cell | 3 | I | T1aNOMX | I | U/U | U/U | U/U | M/M | U/U | M/M |
| 56 | 56M | Clear cell | 3.5 | I | T1aN0MX | I | U/U | U/U | U/U | U/U | U/U | M/M |
| 57 | 62M | Clear cell | 2.5 | I–II | T1aN0MX | I | U/U | U/U | U/U | U/U | U/U | M/M |
| 62 | 61M | Clear cell | 2 | II | T1aN0MX | I | M/M | U/U | U/U | U/U | U/U | M/M |
| 18 | 70M | Clear cell | 2.8 | II | T1aN0MX | I | M/M | M/M | M/M | U/U | M/M | U/U |
| 46 | 72F | Clear cell | 4 | II | T1aN0MX | I | U/U | U/U | M/M | M/M | U/U | M/M |
| 53 | 60F | Clear cell | 3.5 | II | T1aN0MX | I | U/U | U/U | U/U | U/U | U/U | M/U |
| 54 | 57M | Clear cell | 2.2 | II | T1aN0MX | I | U/U | U/U | U/U | M/M | U/U | U/U |
| 13 | 67M | Clear cell | 4 | II | T1aNOMX | I | M/M | U/U | U/U | U/U | U/U | M/M |
| 3 | 59M | Clear cell | 3.5 | III | T1aN0MX | I | U/U | M/M | U/U | U/U | U/U | U/U |
| 37 | 42M | Clear cell | 4 | III | T1aN0MX | I | U/U | U/U | U/U | U/U | U/U | M/U |
| 10 | 69M | Clear cell | 3 | III | T1aNOMX | I | M/M | M/M | U/U | U/U | M/M | M/M |
| 7 | 78M | Clear cell | 2.5 | IV | T1aNOMX | I | U/U | M/M | U/U | U/U | U/U | U/U |
| 11 | 52M | Clear cell | 4 | IV | T1aNOMX | I | U/U | M/M | U/U | U/U | U/U | U/U |
| 48 | 62M | Clear cell | 6 | I–II | T1bN0MX | I | U/U | U/U | U/U | U/U | U/U | M/M |
| 6 | 74F | Clear cell | 4.4 | II | T1bN0MX | I | U/U | M/M | U/U | U/U | M/M | U/U |
| 5 | 56F | Clear cell | 4.5 | II | T1bN0MX | I | U/U | U/U | U/U | U/U | U/U | M/M |
| 8 | 34F | Clear cell | 5 | II | T1bN0MX | I | U/U | U/U | U/U | U/U | U/U | M/M |
| 49 | 57M | Clear cell | 5.5 | II | T1bN0MX | I | M/M | U/U | U/U | U/U | U/U | U/U |
| 50 | 68M | Clear cell | 5.5 | II | T1bN0MX | I | U/U | U/U | U/U | U/U | U/U | M/U |
| 38 | 61F | Clear cell | 6.5 | II | T1bN0MX | I | U/U | M/M | U/U | U/U | M/M | M/M |
| 55 | 43M | Clear cell | 6 | II–III | T1bN0MX | I | U/U | U/U | U/U | U/U | U/U | M/M |
| 23 | 64F | Clear cell | 5 | III | T1bN0MX | I | U/U | M/M | U/U | U/U | U/U | U/U |
| 34 | 60M | Clear cell | 5.5 | IV | T1bN0MX | I | U/U | M/M | U/U | U/U | U/U | U/U |
| 45 | 61M | Clear cell | 15 | I | T2N0MX | II | U/U | U/U | U/U | U/U | U/U | M/M |
| 59 | 80M | Clear cell | 8.5 | I–II | T2N0MX | II | U/U | M/M | U/U | U/U | U/U | U/U |
| 32 | 52F | Clear cell | 4.5 | II | T2N0MX | II | U/U | M/M | U/U | U/U | U/U | M/M |
| 27 | 49M | Clear cell | 9 | IV | T2N0MX | II | U/U | M/M | U/U | U/U | U/U | M/M |
| 2 | 57F | Clear cell | 3 | II | T3aN0MX | III | U/U | M/M | U/U | U/U | U/U | U/U |
| 41 | 59M | Clear cell | 13 | II | T3aN0MX | III | M/M | U/U | U/U | M/M | U/U | U/U |
| 30 | 59M | Clear cell | 3.5 | III | T3aNOMX | III | U/U | M/M | U/U | U/U | U/U | M/M |
| 4 | 54F | Clear cell | 7 | III | T3aN0MX | III | U/U | M/M | U/U | U/U | U/U | M/M |
| 52 | 63M | Clear cell | 5.5 | III | T3bN0MX | III | U/U | M/M | U/U | U/U | U/U | U/U |
| 19 | 78M | Clear cell | 5.5 | II–III | T3bN2MX | IV | U/U | U/U | M/U | U/U | U/U | U/U |
| 21 | 78F | Clear cell | 9.5 | IV | T2N2MX | IV | U/U | M/M | U/U | U/U | U/U | U/U |
| 58 | 78M | RCC unclassified | 10 | IV | T3bN0MX | III | U/U | M/M | U/U | U/U | U/U | M/M |
| 33 | 73F | Papillary | 2.5 | I | T1aN0MX | I | U/U | M/M | M/M | M/M | M/M | U/U |
| 25 | 63M | Papillary | 3 | III | T1aNOMX | I | U/U | M/M | U/U | U/U | U/U | M/M |
| 15 | 30F | Papillary | 4 | III | T1aNOMX | I | U/U | M/M | U/U | U/U | M/M | M/M |
| 20 | 34M | Papillary | 7.5 | II | T2NOMX | II | U/U | M/M | U/U | U/U | U/U | M/M |
| 31 | 69M | Papillary | 3 | III | T3aN0MX | III | U/U | M/U | U/U | U/U | U/U | U/U |
| 28 | 39F | Papillary | 8.5 | IV | T3bNOMX | III | U/U | M/M | M/M | M/M | M/M | U/U |
| 78 | 65F | Chromophobe | 2 | I | T1aN0MX | I | U/U | U/U | U/U | M/M | U/U | M/M |
| 73 | 66M | Chromophobe | 3.5 | I | T1aN0MX | I | U/U | U/U | U/U | M/M | U/U | M/M |
| 24 | 73M | Oncocytoma | 2.5 | U/U | U/U | U/U | U/U | M/U | M/U | |||
| 40 | 69M | Oncocytomaa | 4.1 | U/U | U/U | U/U | U/U | M/M | U/U | |||
| 9 | 59F | Oncocytoma | 6 | U/U | U/U | U/U | M/M | U/U | M/M | |||
| 16 | 70M | Collecting duct | 5.5 | IV | T3aN2MX | IV | U/U | M/M | U/U | U/U | U/U | U/U |
| 44 | 66M | TCC renal pelvis | 2.5 | II | T1N0MX | I | U/U | U/U | U/U | U/U | U/U | M/M |
| 29 | 70M | TCC renal pelvis | 8 | III | T3N0MX | III | U/U | M/M | U/U | U/U | U/U | M/M |
a Patient 40 had multiple oncocytomas and a 2-mm focus of chromophobe carcinoma; M/M, tumor DNA methylated/urine DNA methylated; U/U, tumor DNA unmethylated/urine DNA unmethylated; M/U, tumor DNA methylated/urine DNA unmethylated. No cases of U/M, tumor DNA unmethylated/urine DNA methylated were identified.